董事介绍
注:董事持股数取自最新公司公告
姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
---|---|---|---|---|---|---|
Martin Freed | 男 | Independent Director | 59 | 9.40万美元 | 未持股 | 2020-04-20 |
Rajeev Shah | 男 | Independent Director | 43 | 8.00万美元 | 未持股 | 2020-04-20 |
Lynne Sullivan | 女 | Independent Director | 54 | 9.40万美元 | 未持股 | 2020-04-20 |
Ilan Ganot | 男 | Co-Founder, President, Chief Executive Officer and Director | 46 | 333.59万美元 | 未持股 | 2020-04-20 |
Andrey Zarur | 男 | Co-Founder and Chairman of the Board | 49 | 253.97万美元 | 未持股 | 2020-04-20 |
Matthew Arnold | 男 | Independent Director | 50 | 8.25万美元 | 未持股 | 2020-04-20 |
Robert Huffines | 男 | Independent Director | 55 | 7.50万美元 | 未持股 | 2020-04-20 |
Adam Stone | 男 | Independent Director | 41 | 8.80万美元 | 未持股 | 2020-04-20 |
Sukumar Nagendran | 男 | Independent Director | 54 | 8.25万美元 | 未持股 | 2020-04-20 |
Ian F. Smith | 男 | Director, Consultant | 54 | 未披露 | 未持股 | 2020-04-20 |
Adam Koppel | 男 | Independent Director | 50 | 10.00万美元 | 未持股 | 2020-04-20 |
高管介绍
注:高管持股数取自最新公司公告
姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
---|---|---|---|---|---|---|
Ilan Ganot | 男 | Co-Founder, President, Chief Executive Officer and Director | 46 | 333.59万美元 | 未持股 | 2020-04-20 |
Carl Morris | 男 | Chief Scientific Officer | 50 | 未披露 | 未持股 | 2020-04-20 |
Joel Schneider | 男 | Chief Technology Officer | 35 | 未披露 | 未持股 | 2020-04-20 |
Jennifer Ziolkowski | 女 | Chief Financial Officer and Treasurer | 46 | 102.42万美元 | 未持股 | 2020-04-20 |
Lynette Herscha | 女 | Chief Legal Officer and Secretary | 48 | 未披露 | 未持股 | 2020-04-20 |
董事简历
中英对照 |  中文 |  英文- Martin Freed
-
Martin Freed, 他是医学博士。他是我们公司的创始成员,也曾担任我们的首席医疗官(2010年12月以来)。加入我们公司之前,他拥有广泛治疗领域(包括代谢疾病、心血管疾病、炎症性疾病、皮肤疾病和肿瘤)超过20年的药物开发经验,以及1到4期临床试验阶段经验。创立我们公司之前,他曾担任Avila Therapeutics公司(Avila)的代理首席医疗官(从2010年1月到2011年3月),在那里他提供药物开发和商业化领域的咨询服务。为Avila公司提供咨询服务之前,他曾担任Adnexus Therapeutics公司的首席医疗官(从2007年6月到2008年9月),在那里他为临床药理学和发展战略提供行政和医学领导,他也曾担任Vitae Pharmaceuticals公司(Vitae)的首席医疗官(从2005年4月到2007年1月),在那里他曾领导临床前和临床发展和定义公司战略方向和外部关系建筑的方面。Before Vitae, 他曾任职GlaxoSmithKline公司及其前身公司(SmithKline Beecham Pharmaceuticals,SmithKline Beecham)近14年,在那里他曾担任多种职务,包括副总裁,负责代谢治疗领域的临床开发和医疗事务。他已经撰写了100出版物或报告。他获得内科,肾脏学和临床药理学专业证书 。他曾在Temple University Hospital进行内科住院实习,也曾获得Yale-New Haven Hospital肾脏学奖学金。作为the American College of Physicians的会员,他获得了the University of Delaware的荣誉生物学学士学位,以及Pennsylvania State University’s College of Medicine的医学博士学位。
Martin Freed has served as a member of our Board of Directors since June 2016. Dr. Freed has served as an independent consultant to several private pharmaceutical, biotechnology, and healthcare companies, specializing in clinical and general pharmaceutical development and clinical and regulatory strategy since February 2015. He co-founded and served as Chief Medical Officer of Civitas Therapeutics, Inc., from December 2010 to October 2014 acquired by Acorda Therapeutics, Inc. (“Acorda”), and as Senior Vice President, Clinical Development of Acorda from October 2014 through January 2015. In addition, Dr. Freed has served as Chief Medical Officer and has provided strategic and operational planning and execution, as well as medical leadership for clinical pharmacology and development strategy and preclinical development for multiple pharmaceutical companies throughout his career. These companies include Avila Therapeutics, Inc., Taligen Therapeutics, Adnexus Therapeutics, Inc. (acquired by Bristol-Myers Squibb), and Vitae Pharmaceuticals, Inc. Dr. Freed spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals, where he served numerous roles including Vice President, Clinical Development and Medical Affairs in the metabolism therapeutic area. Dr. Freed currently serves as an independent director for Solid Biosciences Inc. and Sojournix, Inc., and previously served as an independent director of InteKrin Therapeutics Inc. from 2007 to 2010. He has authored over 100 publications or presentations. Dr. Freed has been Board Certified in Internal Medicine, Nephrology and Clinical Pharmacology. He performed his internal medicine residency at Temple University Hospital and nephrology fellowship at Yale-New Haven Hospital. A Fellow of the American College of Physicians, Dr. Freed received his B.S. with distinction in Biology from the University of Delaware and M.D. from Pennsylvania State University’s College of Medicine. - Martin Freed, 他是医学博士。他是我们公司的创始成员,也曾担任我们的首席医疗官(2010年12月以来)。加入我们公司之前,他拥有广泛治疗领域(包括代谢疾病、心血管疾病、炎症性疾病、皮肤疾病和肿瘤)超过20年的药物开发经验,以及1到4期临床试验阶段经验。创立我们公司之前,他曾担任Avila Therapeutics公司(Avila)的代理首席医疗官(从2010年1月到2011年3月),在那里他提供药物开发和商业化领域的咨询服务。为Avila公司提供咨询服务之前,他曾担任Adnexus Therapeutics公司的首席医疗官(从2007年6月到2008年9月),在那里他为临床药理学和发展战略提供行政和医学领导,他也曾担任Vitae Pharmaceuticals公司(Vitae)的首席医疗官(从2005年4月到2007年1月),在那里他曾领导临床前和临床发展和定义公司战略方向和外部关系建筑的方面。Before Vitae, 他曾任职GlaxoSmithKline公司及其前身公司(SmithKline Beecham Pharmaceuticals,SmithKline Beecham)近14年,在那里他曾担任多种职务,包括副总裁,负责代谢治疗领域的临床开发和医疗事务。他已经撰写了100出版物或报告。他获得内科,肾脏学和临床药理学专业证书 。他曾在Temple University Hospital进行内科住院实习,也曾获得Yale-New Haven Hospital肾脏学奖学金。作为the American College of Physicians的会员,他获得了the University of Delaware的荣誉生物学学士学位,以及Pennsylvania State University’s College of Medicine的医学博士学位。
- Martin Freed has served as a member of our Board of Directors since June 2016. Dr. Freed has served as an independent consultant to several private pharmaceutical, biotechnology, and healthcare companies, specializing in clinical and general pharmaceutical development and clinical and regulatory strategy since February 2015. He co-founded and served as Chief Medical Officer of Civitas Therapeutics, Inc., from December 2010 to October 2014 acquired by Acorda Therapeutics, Inc. (“Acorda”), and as Senior Vice President, Clinical Development of Acorda from October 2014 through January 2015. In addition, Dr. Freed has served as Chief Medical Officer and has provided strategic and operational planning and execution, as well as medical leadership for clinical pharmacology and development strategy and preclinical development for multiple pharmaceutical companies throughout his career. These companies include Avila Therapeutics, Inc., Taligen Therapeutics, Adnexus Therapeutics, Inc. (acquired by Bristol-Myers Squibb), and Vitae Pharmaceuticals, Inc. Dr. Freed spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals, where he served numerous roles including Vice President, Clinical Development and Medical Affairs in the metabolism therapeutic area. Dr. Freed currently serves as an independent director for Solid Biosciences Inc. and Sojournix, Inc., and previously served as an independent director of InteKrin Therapeutics Inc. from 2007 to 2010. He has authored over 100 publications or presentations. Dr. Freed has been Board Certified in Internal Medicine, Nephrology and Clinical Pharmacology. He performed his internal medicine residency at Temple University Hospital and nephrology fellowship at Yale-New Haven Hospital. A Fellow of the American College of Physicians, Dr. Freed received his B.S. with distinction in Biology from the University of Delaware and M.D. from Pennsylvania State University’s College of Medicine.
- Rajeev Shah
-
Rajeev Shah,2013年9月以来,他一直担任我们董事会的成员。他是RA Capital Management公司(一个投资咨询公司,一直在投资于卫生保健公司)的合伙人和投资组合经理(2002年以来)。2004年加入RA Capital公司之前,他曾担任Altus Pharmaceuticals公司的高级项目负责人。他持有Cornell University的化学学士学位。
Rajeev Shah has served as a member of our Board of Directors since March 2017. Mr. Shah has been a managing partner at RA Capital Management, L.P., a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics, since 2004. Mr. Shah is also a member of the board of directors of Eidos Therapeutics, Inc., Kala Pharmaceuticals, Inc., Satsuma Pharmaceuticals, Inc.,. and Black Diamond Therapeutics, Inc., each a public biopharmaceutical company. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals, Inc. from June 2015 through April 2018 and Ra Pharmaceuticals, Inc. from July 2015 through April 2020 both public pharmaceutical companies. Mr. Shah received a B.A. in Chemistry from Cornell University. - Rajeev Shah,2013年9月以来,他一直担任我们董事会的成员。他是RA Capital Management公司(一个投资咨询公司,一直在投资于卫生保健公司)的合伙人和投资组合经理(2002年以来)。2004年加入RA Capital公司之前,他曾担任Altus Pharmaceuticals公司的高级项目负责人。他持有Cornell University的化学学士学位。
- Rajeev Shah has served as a member of our Board of Directors since March 2017. Mr. Shah has been a managing partner at RA Capital Management, L.P., a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics, since 2004. Mr. Shah is also a member of the board of directors of Eidos Therapeutics, Inc., Kala Pharmaceuticals, Inc., Satsuma Pharmaceuticals, Inc.,. and Black Diamond Therapeutics, Inc., each a public biopharmaceutical company. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals, Inc. from June 2015 through April 2018 and Ra Pharmaceuticals, Inc. from July 2015 through April 2020 both public pharmaceutical companies. Mr. Shah received a B.A. in Chemistry from Cornell University.
- Lynne Sullivan
-
Lynne Sullivan自2017年12月以来一直担任我们的董事会成员。Sullivan女士于2019年8月从Compass Therapeutics,LLC退休,自2018年12月起担任首席财务官。此前,沙利文女士最近于2016年9月至2018年12月担任BiogenInc.财务高级副总裁。在此之前,Sullivan女士于2015年6月至2018年12月担任高级副总裁,税务和公司财务主管。2008年4月至2015年6月,沙利文女士还担任税务Vice President。在BiogenInc.,沙利文女士负责Biogen&;8217;S的财务规划与分析、公司税和公司融资集团,其中包括长期规划、资本配置项目的所有权以及并购/业务发展的财务方面。2000年1月至2008年4月,Sullivan女士担任EMD Serono的Vice President税务和Merck KGaA的北美税务Vice President。Sullivan女士是Biomx Inc.和Solid Biosciences LLC的董事会成员,自2015年起担任审计委员会主席。Sullivan女士拥有萨福克大学(Suffolk University)会计学士学位和本特利学院(Bentley College)税务硕士学位。Sullivan女士担任了20多年的注册会计师。
Lynne Sullivan has served as our Chief Financial Officer since July 2020 and Head of Corporate Development since January 29 2021. Previously, Ms. Sullivan was Chief Financial Officer at Compass Therapeutics, LLC from December 2018 to August 2019. Prior to that, Ms. Sullivan most recently served as Senior Vice President of Finance for Biogen Inc. NASDAQ: BIIB from September 2016 to December 2018. Prior to joining Biogen, Ms. Sullivan served as Senior Vice President, Tax and Corporate Finance for Biogen from June 2015 to December 2018 and served as Vice President, Tax for Biogen from April 2008 to June 2015. From January 2000 through April 2008 Ms. Sullivan served as Vice President Tax for EMD Serono and the Vice President of Tax for North America at Merck KgaA. Ms. Sullivan also currently serves as a member of the boards of directors and as chair of the audit committees of a number of public biopharmaceutical companies, including Solid Biosciences Inc., Inozyme Pharma, and BiomX Inc. Ms. Sullivan holds an M.S. in taxation from Bentley University and a B.S.B.A. from Suffolk University. - Lynne Sullivan自2017年12月以来一直担任我们的董事会成员。Sullivan女士于2019年8月从Compass Therapeutics,LLC退休,自2018年12月起担任首席财务官。此前,沙利文女士最近于2016年9月至2018年12月担任BiogenInc.财务高级副总裁。在此之前,Sullivan女士于2015年6月至2018年12月担任高级副总裁,税务和公司财务主管。2008年4月至2015年6月,沙利文女士还担任税务Vice President。在BiogenInc.,沙利文女士负责Biogen&;8217;S的财务规划与分析、公司税和公司融资集团,其中包括长期规划、资本配置项目的所有权以及并购/业务发展的财务方面。2000年1月至2008年4月,Sullivan女士担任EMD Serono的Vice President税务和Merck KGaA的北美税务Vice President。Sullivan女士是Biomx Inc.和Solid Biosciences LLC的董事会成员,自2015年起担任审计委员会主席。Sullivan女士拥有萨福克大学(Suffolk University)会计学士学位和本特利学院(Bentley College)税务硕士学位。Sullivan女士担任了20多年的注册会计师。
- Lynne Sullivan has served as our Chief Financial Officer since July 2020 and Head of Corporate Development since January 29 2021. Previously, Ms. Sullivan was Chief Financial Officer at Compass Therapeutics, LLC from December 2018 to August 2019. Prior to that, Ms. Sullivan most recently served as Senior Vice President of Finance for Biogen Inc. NASDAQ: BIIB from September 2016 to December 2018. Prior to joining Biogen, Ms. Sullivan served as Senior Vice President, Tax and Corporate Finance for Biogen from June 2015 to December 2018 and served as Vice President, Tax for Biogen from April 2008 to June 2015. From January 2000 through April 2008 Ms. Sullivan served as Vice President Tax for EMD Serono and the Vice President of Tax for North America at Merck KgaA. Ms. Sullivan also currently serves as a member of the boards of directors and as chair of the audit committees of a number of public biopharmaceutical companies, including Solid Biosciences Inc., Inozyme Pharma, and BiomX Inc. Ms. Sullivan holds an M.S. in taxation from Bentley University and a B.S.B.A. from Suffolk University.
- Ilan Ganot
-
Ilan Ganot是我们的联合创始人之一,自2013年成立以来一直担任我们的首席执行官和董事会成员。Ganot先生自2018年6月起担任我们的总裁。此前,加诺特曾于2011年9月至2013年9月担任全球领先的金融服务公司摩根大通集团(citigroup)的投资银行家。Ganot从2008年10月到2011年8月担任Nomura Securities Co.,Ltd.(一家证券和投资银行公司)银行家,从2003年9月到2008年9月担任Lehman Brothers(一家全球金融服务公司)银行家。Ganot先生在伦敦商学院(London Business School)获得工商管理硕士学位,并持有以色列赫兹利亚(Herzliya)跨学科中心的法律和商业学位。Ganot先生还在以色列从事公司法,曾是以色列国防军上尉。
Ilan Ganot is one of our co-founders and has served as our Chief Executive Officer and as a member of our Board of Directors since our inception in 2013. Mr. Ganot has served as our President since June 2018. Previously, Mr. Ganot served as an investment banker at JPMorgan Chase & Co., a leading global financial services firm, from September 2011 to September 2013. From October 2008 to August 2011 Mr. Ganot served as a banker at Nomura Securities Co., Ltd., a securities and investment banking company, and from September 2003 to September 2008 at Lehman Brothers, a global financial services firm. Mr. Ganot received his M.B.A. from London Business School and holds law and business degrees from the Interdisciplinary Center in Herzliya, Israel. Mr. Ganot also practiced corporate law in Israel and was a Captain in the Israeli Defense Forces. - Ilan Ganot是我们的联合创始人之一,自2013年成立以来一直担任我们的首席执行官和董事会成员。Ganot先生自2018年6月起担任我们的总裁。此前,加诺特曾于2011年9月至2013年9月担任全球领先的金融服务公司摩根大通集团(citigroup)的投资银行家。Ganot从2008年10月到2011年8月担任Nomura Securities Co.,Ltd.(一家证券和投资银行公司)银行家,从2003年9月到2008年9月担任Lehman Brothers(一家全球金融服务公司)银行家。Ganot先生在伦敦商学院(London Business School)获得工商管理硕士学位,并持有以色列赫兹利亚(Herzliya)跨学科中心的法律和商业学位。Ganot先生还在以色列从事公司法,曾是以色列国防军上尉。
- Ilan Ganot is one of our co-founders and has served as our Chief Executive Officer and as a member of our Board of Directors since our inception in 2013. Mr. Ganot has served as our President since June 2018. Previously, Mr. Ganot served as an investment banker at JPMorgan Chase & Co., a leading global financial services firm, from September 2011 to September 2013. From October 2008 to August 2011 Mr. Ganot served as a banker at Nomura Securities Co., Ltd., a securities and investment banking company, and from September 2003 to September 2008 at Lehman Brothers, a global financial services firm. Mr. Ganot received his M.B.A. from London Business School and holds law and business degrees from the Interdisciplinary Center in Herzliya, Israel. Mr. Ganot also practiced corporate law in Israel and was a Captain in the Israeli Defense Forces.
- Andrey Zarur
-
Andrey Zarur博士是我们的联合创始人之一,自2013年成立以来一直担任我们的董事会主席。Zarur博士于2008年8月共同创立了Greenlight Biosciences Inc.,这是一家生物技术公司,目前担任其董事长兼首席执行官。从2006年1月到2014年8月,他曾担任Kodiak Venture Partners公司(风险投资公司)的管理普通合伙人。Zarur博士还担任多家私人公司的董事会成员。Zarur博士拥有麻省理工学院(Massachusetts Institute of Technology)的硕士学位和博士学位,以及墨西哥国立自治大学(Universidad Nacional Aut&243;Noma de M&233;Xico)的本科学位。
Andrey Zarur, Ph.D. is one of our co-founders and has served as the Chairman of our Board of Directors since our inception in 2013. Dr. Zarur co-founded GreenLight Biosciences Inc., a biotechnology company, in August 2008 and currently serves as its Chairman and Chief Executive Officer. From January 2006 to August 2014 he served as Managing General Partner of Kodiak Venture Partners, a venture capital firm. Dr. Zarur also serves as a member of the board of directors for a number of private companies. Dr. Zarur holds an M.S. and a Ph.D. from Massachusetts Institute of Technology and an undergraduate degree from Universidad Nacional Autónoma de México. - Andrey Zarur博士是我们的联合创始人之一,自2013年成立以来一直担任我们的董事会主席。Zarur博士于2008年8月共同创立了Greenlight Biosciences Inc.,这是一家生物技术公司,目前担任其董事长兼首席执行官。从2006年1月到2014年8月,他曾担任Kodiak Venture Partners公司(风险投资公司)的管理普通合伙人。Zarur博士还担任多家私人公司的董事会成员。Zarur博士拥有麻省理工学院(Massachusetts Institute of Technology)的硕士学位和博士学位,以及墨西哥国立自治大学(Universidad Nacional Aut&243;Noma de M&233;Xico)的本科学位。
- Andrey Zarur, Ph.D. is one of our co-founders and has served as the Chairman of our Board of Directors since our inception in 2013. Dr. Zarur co-founded GreenLight Biosciences Inc., a biotechnology company, in August 2008 and currently serves as its Chairman and Chief Executive Officer. From January 2006 to August 2014 he served as Managing General Partner of Kodiak Venture Partners, a venture capital firm. Dr. Zarur also serves as a member of the board of directors for a number of private companies. Dr. Zarur holds an M.S. and a Ph.D. from Massachusetts Institute of Technology and an undergraduate degree from Universidad Nacional Autónoma de México.
- Matthew Arnold
-
Matthew Arnold是Solid的创始成员之一,自2013年成立以来一直担任我们的董事会成员。Arnold先生自2009年以来一直与英国和欧洲的初创企业积极合作,主要是在技术和清洁技术领域。他持有弗吉尼亚大学(the University of Virginia)的硕士学位,以及杜克大学(Duke University)的学士学位。
Matthew Arnold is a founding member of Solid and has served as a member of our Board of Directors since our inception in 2013. A former energy executive, since 2009 Mr. Arnold has been actively working with startup businesses in the United Kingdom and Europe, primarily in the technology and clean tech sectors. He holds an M.S. from the University of Virginia and a B.A. from Duke University. - Matthew Arnold是Solid的创始成员之一,自2013年成立以来一直担任我们的董事会成员。Arnold先生自2009年以来一直与英国和欧洲的初创企业积极合作,主要是在技术和清洁技术领域。他持有弗吉尼亚大学(the University of Virginia)的硕士学位,以及杜克大学(Duke University)的学士学位。
- Matthew Arnold is a founding member of Solid and has served as a member of our Board of Directors since our inception in 2013. A former energy executive, since 2009 Mr. Arnold has been actively working with startup businesses in the United Kingdom and Europe, primarily in the technology and clean tech sectors. He holds an M.S. from the University of Virginia and a B.A. from Duke University.
- Robert Huffines
-
Robert Huffines自2013年12月以来一直担任我们的董事会成员。Huffines先生于1991年加入全球领先的金融服务公司摩根大通(J.P.Morgan),目前担任投资银行业务全球董事长,自2017年2月起担任该职位。在摩根大通的整个职业生涯中,Huffines先生担任过多个领导职位,包括2002年至2010年担任全球梦百合投资银行集团联席主管,2011年至2017年1月担任副董事长。Huffines先生在弗吉尼亚大学(University of Virginia)获得工商管理硕士学位,在北卡罗莱纳大学(University of North Carolina)获得工商管理学士学位。
Robert Huffines has served as a member of our Board of Directors since December 2013. Mr. Huffines joined J.P. Morgan, a leading global financial services firm, in 1991 and currently serves as the Global Chairman of Investment Banking, a position he has held since February 2017. Throughout his career at J.P. Morgan, Mr. Huffines has held various leadership positions, including serving as Co-Head of the Global Healthcare Investment Banking Group from 2002 to 2010 and Vice Chairman from 2011 to January 2017. Mr. Huffines received an M.B.A. from the University of Virginia and a B.A. from the University of North Carolina. - Robert Huffines自2013年12月以来一直担任我们的董事会成员。Huffines先生于1991年加入全球领先的金融服务公司摩根大通(J.P.Morgan),目前担任投资银行业务全球董事长,自2017年2月起担任该职位。在摩根大通的整个职业生涯中,Huffines先生担任过多个领导职位,包括2002年至2010年担任全球梦百合投资银行集团联席主管,2011年至2017年1月担任副董事长。Huffines先生在弗吉尼亚大学(University of Virginia)获得工商管理硕士学位,在北卡罗莱纳大学(University of North Carolina)获得工商管理学士学位。
- Robert Huffines has served as a member of our Board of Directors since December 2013. Mr. Huffines joined J.P. Morgan, a leading global financial services firm, in 1991 and currently serves as the Global Chairman of Investment Banking, a position he has held since February 2017. Throughout his career at J.P. Morgan, Mr. Huffines has held various leadership positions, including serving as Co-Head of the Global Healthcare Investment Banking Group from 2002 to 2010 and Vice Chairman from 2011 to January 2017. Mr. Huffines received an M.B.A. from the University of Virginia and a B.A. from the University of North Carolina.
- Adam Stone
-
Adam Stone是我们的首席执行官,也是我们的董事会成员。Stone于2006年加入Perceptive Advisors,自2012年起担任首席投资官,是Perceptive Advisors’;信贷机会和风险基金内部投资委员会成员。斯通先生目前还担任Arya Sciences Acquisition Corp Iii公司(纳斯达克市场代码:ARYA)的首席执行官和董事会成员,以及Solid Biosciences公司(纳斯达克市场代码:SLDB)、雷诺维亚公司和Xontogeny公司的董事会成员,这些公司都是Perceptive Advisors公司的投资组合公司。随着ARYA Sciences AcquisitionCorp.与Immatics Biotechnologies GmbH的业务合并于2020年7月完成,Stone先生还担任Immatics N.V.(纳斯达克市场代码:IMTX)的监事会成员。加入Perceptive Advisors公司之前,他曾担任Ursus Capital公司的高级分析师(从2001年到2006年),在那里他专注于生物技术和专业制药。Stone先生在Ursus Capital任职期间,Stone先生专注于生物技术和专业制药。Stone先生以优异成绩毕业于普林斯顿大学(Princeton University),获得分子生物学学士学位。
Adam Stone has served as a member of our board of directors since October 2019. Since July 2021 and February 2021 respectively, Mr. Stone has served as the Chief Executive Officer of ARYA Sciences Acquisition Corp V and ARYA Sciences Acquisition Corp IV, respectively, and as a member of their board of directors. Mr. Stone previously served as the chief executive officer and a member of the board of directors of ARYA Sciences Acquisitions Corps I, II, and III. Mr. Stone joined Perceptive Advisors, a life sciences focused investing firm and affiliate of the Company, in 2006 and has served as Chief Investment Officer since 2012 and is a member of the internal investment committees of Perceptive Advisors' credit opportunities and venture funds. Mr. Stone previously served as a Senior Analyst at Ursus Capital from 2001 to 2006 where he focused on biotechnology and specialty pharmaceuticals. Mr. Stone has also served as a member of the boards of directors of Solid Biosciences since November 2015 and Immatics since July 2020. Mr. Stone earned a bachelor's degree in molecular biology from Princeton University. - Adam Stone是我们的首席执行官,也是我们的董事会成员。Stone于2006年加入Perceptive Advisors,自2012年起担任首席投资官,是Perceptive Advisors’;信贷机会和风险基金内部投资委员会成员。斯通先生目前还担任Arya Sciences Acquisition Corp Iii公司(纳斯达克市场代码:ARYA)的首席执行官和董事会成员,以及Solid Biosciences公司(纳斯达克市场代码:SLDB)、雷诺维亚公司和Xontogeny公司的董事会成员,这些公司都是Perceptive Advisors公司的投资组合公司。随着ARYA Sciences AcquisitionCorp.与Immatics Biotechnologies GmbH的业务合并于2020年7月完成,Stone先生还担任Immatics N.V.(纳斯达克市场代码:IMTX)的监事会成员。加入Perceptive Advisors公司之前,他曾担任Ursus Capital公司的高级分析师(从2001年到2006年),在那里他专注于生物技术和专业制药。Stone先生在Ursus Capital任职期间,Stone先生专注于生物技术和专业制药。Stone先生以优异成绩毕业于普林斯顿大学(Princeton University),获得分子生物学学士学位。
- Adam Stone has served as a member of our board of directors since October 2019. Since July 2021 and February 2021 respectively, Mr. Stone has served as the Chief Executive Officer of ARYA Sciences Acquisition Corp V and ARYA Sciences Acquisition Corp IV, respectively, and as a member of their board of directors. Mr. Stone previously served as the chief executive officer and a member of the board of directors of ARYA Sciences Acquisitions Corps I, II, and III. Mr. Stone joined Perceptive Advisors, a life sciences focused investing firm and affiliate of the Company, in 2006 and has served as Chief Investment Officer since 2012 and is a member of the internal investment committees of Perceptive Advisors' credit opportunities and venture funds. Mr. Stone previously served as a Senior Analyst at Ursus Capital from 2001 to 2006 where he focused on biotechnology and specialty pharmaceuticals. Mr. Stone has also served as a member of the boards of directors of Solid Biosciences since November 2015 and Immatics since July 2020. Mr. Stone earned a bachelor's degree in molecular biology from Princeton University.
- Sukumar Nagendran
-
Sukumar Nagendran自2020年7月以来一直担任我们的董事会成员。Nagendran博士自2018年9月起担任生命科学公司Solid BiosciencesInc.的董事会成员,目前担任生物技术公司Encode Therapeutics,Inc.的顾问。在与Immunovant,Inc.合并之前,他曾于2019年3月至2019年12月担任特殊目的收购公司Health Sciences Acquisition Corp.的董事会成员。Nagendran博士最近于2015年9月至2018年5月担任基因治疗公司Avexis,Inc.(Quest Diagnostics Inc.)的高级副总裁兼首席医疗官,此前曾担任临床实验室Quest Diagnostics Inc.美国和国际业务主管Vice President,从2013年3月到2015年9月。Nagendran博士在罗格斯大学(Rutgers University)获得文学学士学位,在新泽西医学和牙科大学(University of Medicine and Dentistry of New Jersey)获得医学硕士学位,并在明尼苏达州罗彻斯特的梅奥诊所(Mayo Clinic)接受内科培训。
Sukumar Nagendran,has served as Taysha Gene Therapies, Inc. President and Head of Research and Development since December 2022 and as a member of Taysha Gene Therapies, Inc. Board of Directors since July 2020. Dr. Nagendran previously served as President, Research and Development and Chief Medical Officer at Jaguar Gene Therapy, LLC, from February 2020 to December 2022. Dr. Nagendran has served on the board of directors of Solid Biosciences Inc., a publicly traded life sciences company, since September 2018 and currently serves as an advisor to Encoded Therapeutics, Inc., a biotechnology company. He previously served on the board of directors of Health Sciences Acquisition Corp., a special purpose acquisition company, from March 2019 to December 2019 prior to its merger with Immunovant, Inc. Dr. Nagendran most recently served as Senior Vice President and Chief Medical Officer of AveXis, Inc., a publicly traded gene therapy company, from 2015 to May 2018. Dr. Nagendran earned a B.A. from Rutgers University and an M.D. from the University of Medicine and Dentistry of New Jersey and trained in Internal Medicine at Mayo Clinic in Rochester, Minnesota. - Sukumar Nagendran自2020年7月以来一直担任我们的董事会成员。Nagendran博士自2018年9月起担任生命科学公司Solid BiosciencesInc.的董事会成员,目前担任生物技术公司Encode Therapeutics,Inc.的顾问。在与Immunovant,Inc.合并之前,他曾于2019年3月至2019年12月担任特殊目的收购公司Health Sciences Acquisition Corp.的董事会成员。Nagendran博士最近于2015年9月至2018年5月担任基因治疗公司Avexis,Inc.(Quest Diagnostics Inc.)的高级副总裁兼首席医疗官,此前曾担任临床实验室Quest Diagnostics Inc.美国和国际业务主管Vice President,从2013年3月到2015年9月。Nagendran博士在罗格斯大学(Rutgers University)获得文学学士学位,在新泽西医学和牙科大学(University of Medicine and Dentistry of New Jersey)获得医学硕士学位,并在明尼苏达州罗彻斯特的梅奥诊所(Mayo Clinic)接受内科培训。
- Sukumar Nagendran,has served as Taysha Gene Therapies, Inc. President and Head of Research and Development since December 2022 and as a member of Taysha Gene Therapies, Inc. Board of Directors since July 2020. Dr. Nagendran previously served as President, Research and Development and Chief Medical Officer at Jaguar Gene Therapy, LLC, from February 2020 to December 2022. Dr. Nagendran has served on the board of directors of Solid Biosciences Inc., a publicly traded life sciences company, since September 2018 and currently serves as an advisor to Encoded Therapeutics, Inc., a biotechnology company. He previously served on the board of directors of Health Sciences Acquisition Corp., a special purpose acquisition company, from March 2019 to December 2019 prior to its merger with Immunovant, Inc. Dr. Nagendran most recently served as Senior Vice President and Chief Medical Officer of AveXis, Inc., a publicly traded gene therapy company, from 2015 to May 2018. Dr. Nagendran earned a B.A. from Rutgers University and an M.D. from the University of Medicine and Dentistry of New Jersey and trained in Internal Medicine at Mayo Clinic in Rochester, Minnesota.
- Ian F. Smith
-
Ian F. Smith担任执行副总裁和财务总监(2006年2月担任此职位)。2003年11月-2006年2月他担任高级副总裁和财务总监;2001年10月-2003年11月他担任副总裁和财务总监。在加入公司之前,他担任Ernst & Young 有限责任合伙公司(Ernst & Young LLP,一家会计公司)的生命科学和技术实践部门合伙人(1999-2001年)。他最初在1987年加入Ernst & Young(英国(U.K。)公司),1995年加入它的波士顿办事处(Boston office)。他目前担任Acorda Therapeutics股份有限公司(Acorda Therapeutics, Inc.,一家药物开发公司)和Infinity Pharmaceuticals股份有限公司(Infinity Pharmaceuticals, Inc.,一家药物开发公司)的董事会成员。他拥有英国曼彻斯特城市大学(Manchester Metropolitan University, U.K。)财务和会计学士学位,是美国注册会计师协会(American Institute of Certified Public Accountants)的成员,也是英格兰和威尔士(England and Wales)的注册会计师。
Ian F. Smith has served as a member of our Board of Directors since April 2020. Mr. Smith has served as a consultant to us since February 2020. Mr. Smith previously served as Executive Vice President and Chief Operating Officer of Vertex Pharmaceuticals, a public biotechnology company, from September 2017 to January 2019 and prior to that served as Chief Financial Officer from October 2001 to September 2017. Prior to joining Vertex in 2001 Mr. Smith served as a partner in the Life Science and Technology Practice of Ernst & Young LLP, an accounting firm. Mr. Smith currently serves as director and chairman of the board of ViaCyte, Inc., a private biotechnology company. Previously, Mr. Smith served on the board of directors of Acorda Therapeutics and Infinity Pharmaceuticals, both public biotechnology companies, as well as other private biotechnology companies. He received a B.A. with honors in accounting and finance from Manchester Metropolitan UK. - Ian F. Smith担任执行副总裁和财务总监(2006年2月担任此职位)。2003年11月-2006年2月他担任高级副总裁和财务总监;2001年10月-2003年11月他担任副总裁和财务总监。在加入公司之前,他担任Ernst & Young 有限责任合伙公司(Ernst & Young LLP,一家会计公司)的生命科学和技术实践部门合伙人(1999-2001年)。他最初在1987年加入Ernst & Young(英国(U.K。)公司),1995年加入它的波士顿办事处(Boston office)。他目前担任Acorda Therapeutics股份有限公司(Acorda Therapeutics, Inc.,一家药物开发公司)和Infinity Pharmaceuticals股份有限公司(Infinity Pharmaceuticals, Inc.,一家药物开发公司)的董事会成员。他拥有英国曼彻斯特城市大学(Manchester Metropolitan University, U.K。)财务和会计学士学位,是美国注册会计师协会(American Institute of Certified Public Accountants)的成员,也是英格兰和威尔士(England and Wales)的注册会计师。
- Ian F. Smith has served as a member of our Board of Directors since April 2020. Mr. Smith has served as a consultant to us since February 2020. Mr. Smith previously served as Executive Vice President and Chief Operating Officer of Vertex Pharmaceuticals, a public biotechnology company, from September 2017 to January 2019 and prior to that served as Chief Financial Officer from October 2001 to September 2017. Prior to joining Vertex in 2001 Mr. Smith served as a partner in the Life Science and Technology Practice of Ernst & Young LLP, an accounting firm. Mr. Smith currently serves as director and chairman of the board of ViaCyte, Inc., a private biotechnology company. Previously, Mr. Smith served on the board of directors of Acorda Therapeutics and Infinity Pharmaceuticals, both public biotechnology companies, as well as other private biotechnology companies. He received a B.A. with honors in accounting and finance from Manchester Metropolitan UK.
- Adam Koppel
-
Adam Koppel,2013年3月起担任本公司董事。他从2003年11月起,担任Brookside Capital, LLC的总经理,这是Bain Capital的上市股票联属公司。加入Brookside Capital, LLC之前,他是McKinsey & Company的初级合伙人,为制药和生物技术行业的公司提供咨询服务。他在University of Pennsylvania School of Medicine获得了医学博士和学术博士学位,在Wharton School of the University of Pennsylvania获得工商管理硕士学位,在Harvard University获得学士学位。
Adam Koppel, the Chairman of our board of directors since August 2020 initially joined Bain Capital in 2003 and is a Managing Director on the investment team and a member of the internal investment committee of Bain Capital Life Sciences. Prior to co-founding Bain Capital Life Sciences in 2016 Dr. Koppel worked within the healthcare vertical of Bain Capital Public Equity from 2003 to 2014. Dr. Koppel also served as Executive Vice President of Corporate Development and Chief Strategy Officer of Biogen Nasdaq: BIIB from 2014 to 2016 and as a director of ViaCyte from November 2018 to January 2021. Dr. Koppel currently serves on the boards of directors of Aptinyx (Nasdaq: APTX), Cerevel Therapeutics Holdings (Nasdaq: CERE, CEREW), Dicerna Pharmaceuticals (Nasdaq: DRNA), Solid Biosciences (Nasdaq: SLDB), which are portfolio companies of Bain Capital Life Sciences, and public company Foghorn Therapeutics (Nasdaq: FHTX). Prior to initially joining Bain Capital, Dr. Koppel was an Associate Principal at McKinsey & Co, where he served a variety of healthcare companies. Dr. Koppel earned an MD and PhD in neuroscience from the University of Pennsylvania School of Medicine, an MBA from the University of Pennsylvania, where he was a Palmer Scholar, and an AB and AM, magna cum laude, in history and science from Harvard University. - Adam Koppel,2013年3月起担任本公司董事。他从2003年11月起,担任Brookside Capital, LLC的总经理,这是Bain Capital的上市股票联属公司。加入Brookside Capital, LLC之前,他是McKinsey & Company的初级合伙人,为制药和生物技术行业的公司提供咨询服务。他在University of Pennsylvania School of Medicine获得了医学博士和学术博士学位,在Wharton School of the University of Pennsylvania获得工商管理硕士学位,在Harvard University获得学士学位。
- Adam Koppel, the Chairman of our board of directors since August 2020 initially joined Bain Capital in 2003 and is a Managing Director on the investment team and a member of the internal investment committee of Bain Capital Life Sciences. Prior to co-founding Bain Capital Life Sciences in 2016 Dr. Koppel worked within the healthcare vertical of Bain Capital Public Equity from 2003 to 2014. Dr. Koppel also served as Executive Vice President of Corporate Development and Chief Strategy Officer of Biogen Nasdaq: BIIB from 2014 to 2016 and as a director of ViaCyte from November 2018 to January 2021. Dr. Koppel currently serves on the boards of directors of Aptinyx (Nasdaq: APTX), Cerevel Therapeutics Holdings (Nasdaq: CERE, CEREW), Dicerna Pharmaceuticals (Nasdaq: DRNA), Solid Biosciences (Nasdaq: SLDB), which are portfolio companies of Bain Capital Life Sciences, and public company Foghorn Therapeutics (Nasdaq: FHTX). Prior to initially joining Bain Capital, Dr. Koppel was an Associate Principal at McKinsey & Co, where he served a variety of healthcare companies. Dr. Koppel earned an MD and PhD in neuroscience from the University of Pennsylvania School of Medicine, an MBA from the University of Pennsylvania, where he was a Palmer Scholar, and an AB and AM, magna cum laude, in history and science from Harvard University.
高管简历
中英对照 |  中文 |  英文- Ilan Ganot
Ilan Ganot是我们的联合创始人之一,自2013年成立以来一直担任我们的首席执行官和董事会成员。Ganot先生自2018年6月起担任我们的总裁。此前,加诺特曾于2011年9月至2013年9月担任全球领先的金融服务公司摩根大通集团(citigroup)的投资银行家。Ganot从2008年10月到2011年8月担任Nomura Securities Co.,Ltd.(一家证券和投资银行公司)银行家,从2003年9月到2008年9月担任Lehman Brothers(一家全球金融服务公司)银行家。Ganot先生在伦敦商学院(London Business School)获得工商管理硕士学位,并持有以色列赫兹利亚(Herzliya)跨学科中心的法律和商业学位。Ganot先生还在以色列从事公司法,曾是以色列国防军上尉。
Ilan Ganot is one of our co-founders and has served as our Chief Executive Officer and as a member of our Board of Directors since our inception in 2013. Mr. Ganot has served as our President since June 2018. Previously, Mr. Ganot served as an investment banker at JPMorgan Chase & Co., a leading global financial services firm, from September 2011 to September 2013. From October 2008 to August 2011 Mr. Ganot served as a banker at Nomura Securities Co., Ltd., a securities and investment banking company, and from September 2003 to September 2008 at Lehman Brothers, a global financial services firm. Mr. Ganot received his M.B.A. from London Business School and holds law and business degrees from the Interdisciplinary Center in Herzliya, Israel. Mr. Ganot also practiced corporate law in Israel and was a Captain in the Israeli Defense Forces.- Ilan Ganot是我们的联合创始人之一,自2013年成立以来一直担任我们的首席执行官和董事会成员。Ganot先生自2018年6月起担任我们的总裁。此前,加诺特曾于2011年9月至2013年9月担任全球领先的金融服务公司摩根大通集团(citigroup)的投资银行家。Ganot从2008年10月到2011年8月担任Nomura Securities Co.,Ltd.(一家证券和投资银行公司)银行家,从2003年9月到2008年9月担任Lehman Brothers(一家全球金融服务公司)银行家。Ganot先生在伦敦商学院(London Business School)获得工商管理硕士学位,并持有以色列赫兹利亚(Herzliya)跨学科中心的法律和商业学位。Ganot先生还在以色列从事公司法,曾是以色列国防军上尉。
- Ilan Ganot is one of our co-founders and has served as our Chief Executive Officer and as a member of our Board of Directors since our inception in 2013. Mr. Ganot has served as our President since June 2018. Previously, Mr. Ganot served as an investment banker at JPMorgan Chase & Co., a leading global financial services firm, from September 2011 to September 2013. From October 2008 to August 2011 Mr. Ganot served as a banker at Nomura Securities Co., Ltd., a securities and investment banking company, and from September 2003 to September 2008 at Lehman Brothers, a global financial services firm. Mr. Ganot received his M.B.A. from London Business School and holds law and business degrees from the Interdisciplinary Center in Herzliya, Israel. Mr. Ganot also practiced corporate law in Israel and was a Captain in the Israeli Defense Forces.
- Carl Morris
Carl Morris博士自2017年6月以来一直担任我们的首席科学官,此前曾于2015年9月至2017年6月担任我们的研究与开发高级副总裁。在加入我们之前,莫里斯博士于2010年1月至2015年8月在辉瑞公司(Pfizer&;8217;S&;8220;Pfizer&;8221;Rare Disease Research Unit)担任多个领导职位,包括担任高级董事,董事和高级首席科学家。任职Pfizer公司之前,Morris博士曾担任Wyeth Pharmaceuticals,Inc.(被Pfizer公司收购的制药公司)的组织修复单元的多种职务。Morris博士曾是波士顿大学医学院(Boston University School of Medicine)的助理教授,也是肌肉与衰老研究单元(Muscle and Aging Research Unit)的创始教员。他也是Breed Nutrition Inc.的联合创始人和董事会成员。Morris博士拥有富兰克林·皮尔斯学院(Franklin Pierce College)生物学学士学位和加州大学洛杉矶分校(UCLA)生理学博士学位。
Carl Morris, Ph.D. has served as our Chief Scientific Officer since June 2017 and previously served as our Senior Vice President of Research and Development from September 2015 to June 2017. Prior to joining us, Dr. Morris held various leadership positions within Pfizer Inc.’s “Pfizer” Rare Disease Research Unit from January 2010 to August 2015 including serving as a Senior Director, Director and Senior Principal Scientist. Prior to Pfizer, Dr. Morris held various positions within the Tissue Repair unit at Wyeth Pharmaceuticals, Inc., a pharmaceutical company acquired by Pfizer. Dr. Morris was an Assistant Professor at Boston University School of Medicine and a founding faculty member of the Muscle and Aging Research Unit. He is also co-founder and a member of the board of directors of Breed Nutrition Inc. Dr. Morris holds a B.A. in Biology from Franklin Pierce College and a Ph.D. in Physiology from UCLA.- Carl Morris博士自2017年6月以来一直担任我们的首席科学官,此前曾于2015年9月至2017年6月担任我们的研究与开发高级副总裁。在加入我们之前,莫里斯博士于2010年1月至2015年8月在辉瑞公司(Pfizer&;8217;S&;8220;Pfizer&;8221;Rare Disease Research Unit)担任多个领导职位,包括担任高级董事,董事和高级首席科学家。任职Pfizer公司之前,Morris博士曾担任Wyeth Pharmaceuticals,Inc.(被Pfizer公司收购的制药公司)的组织修复单元的多种职务。Morris博士曾是波士顿大学医学院(Boston University School of Medicine)的助理教授,也是肌肉与衰老研究单元(Muscle and Aging Research Unit)的创始教员。他也是Breed Nutrition Inc.的联合创始人和董事会成员。Morris博士拥有富兰克林·皮尔斯学院(Franklin Pierce College)生物学学士学位和加州大学洛杉矶分校(UCLA)生理学博士学位。
- Carl Morris, Ph.D. has served as our Chief Scientific Officer since June 2017 and previously served as our Senior Vice President of Research and Development from September 2015 to June 2017. Prior to joining us, Dr. Morris held various leadership positions within Pfizer Inc.’s “Pfizer” Rare Disease Research Unit from January 2010 to August 2015 including serving as a Senior Director, Director and Senior Principal Scientist. Prior to Pfizer, Dr. Morris held various positions within the Tissue Repair unit at Wyeth Pharmaceuticals, Inc., a pharmaceutical company acquired by Pfizer. Dr. Morris was an Assistant Professor at Boston University School of Medicine and a founding faculty member of the Muscle and Aging Research Unit. He is also co-founder and a member of the board of directors of Breed Nutrition Inc. Dr. Morris holds a B.A. in Biology from Franklin Pierce College and a Ph.D. in Physiology from UCLA.
- Joel Schneider
Joel Schneider博士自2017年6月起担任我们的首席技术官兼探索性研究与开发主管。Schneider博士还于2014年3月至2015年3月担任分析师,于2015年3月至2017年1月担任董事,并于2017年1月至2017年6月担任研究与开发Vice President。在加入我们之前,Schneider博士于2013年1月至2014年在哈佛大学(Harvard University)干细胞和再生生物系完成博士后奖学金。他持有Rutgers University的细胞生物学和分子医学博士学位,以及Brandeis University的生物学学士学位。
Joel Schneider, Ph.D. has served as our Chief Technology Officer and Head of Exploratory Research and Development since June 2017. Dr. Schneider also served as an Analyst from March 2014 to March 2015 a Director from March 2015 to January 2017 and our Vice President of Research and Development from January 2017 to June 2017. Prior to joining us, Dr. Schneider completed a postdoctoral fellowship at Harvard University in the Department of Stem Cell and Regenerative Biology from January 2013 to 2014. He holds a Ph.D. in Cell Biology and Molecular Medicine from Rutgers University and a B.A. in Biology from Brandeis University.- Joel Schneider博士自2017年6月起担任我们的首席技术官兼探索性研究与开发主管。Schneider博士还于2014年3月至2015年3月担任分析师,于2015年3月至2017年1月担任董事,并于2017年1月至2017年6月担任研究与开发Vice President。在加入我们之前,Schneider博士于2013年1月至2014年在哈佛大学(Harvard University)干细胞和再生生物系完成博士后奖学金。他持有Rutgers University的细胞生物学和分子医学博士学位,以及Brandeis University的生物学学士学位。
- Joel Schneider, Ph.D. has served as our Chief Technology Officer and Head of Exploratory Research and Development since June 2017. Dr. Schneider also served as an Analyst from March 2014 to March 2015 a Director from March 2015 to January 2017 and our Vice President of Research and Development from January 2017 to June 2017. Prior to joining us, Dr. Schneider completed a postdoctoral fellowship at Harvard University in the Department of Stem Cell and Regenerative Biology from January 2013 to 2014. He holds a Ph.D. in Cell Biology and Molecular Medicine from Rutgers University and a B.A. in Biology from Brandeis University.
- Jennifer Ziolkowski
Jennifer Ziolkowski自2017年5月起担任我们的首席财务官兼财务主管。在加入我们之前,她曾于2014年至2017年担任梦百合公司Philips梦百合北美销售业务主管,并于2012年至2014年担任其北美高级财务总监。Ziolkowski女士从2010年到2012年担任医疗耗材和传感器总监,从2008年到2010年担任Imaging Systems的财务总监,从2007年到2008年担任TransMedics,Inc.的财务高级总监和公司财务总监,TransMedics,Inc.是一家医疗设备公司,并从2001年到2007年在Cytyc Corporation(一家医疗技术公司)担任多个金融和企业发展领导职位。从1996年到2001年,Ziolkowski女士在普华永道会计师事务所(PricewaterhouseCoopers LLP)获得了丰富的经验,在那里她担任高级交易服务顾问,并担任波士顿技术集团的审计高级和工作人员。Ziolkowski女士拥有波士顿学院(Boston College)会计学士学位,是一名注册会计师。
Jennifer Ziolkowski has served as our Chief Financial Officer since March 2021. Prior to joining Vigil, Ms. Ziolkowski was Chief Financial Officer of Solid Biosciences Inc. NASDAQ: SLDB from May 2017 to January 2021 where she played a key role in transforming Solid from a private, preclinical company to a publicly-held, clinical-stage biotech company. Previously, Ms. Ziolkowski held various leadership positions at Philips Healthcare from August 2008 to May 2017 most recently as Head of Sales Operations, North America of Philips Healthcare from 2015 to May 2017. Prior to Phillips, Ms. Ziolkowski was Senior Director of Finance and Corporate Controller of TransMedics, Inc. from April 2007 to July 2008 where she played a critical role in building the company's financial operations. Ms. Ziolkowski established her career within the healthcare industry at Cytyc Corporation (acquired by Hologic, Inc. (NASDAQ:HOLX)) from May 2001 to April 2007. Ms. Ziolkowski began her career at PricewaterhouseCoopers LLP from September 1996 to April 2001. Ms. Ziolkowski holds a BS in Accounting from Boston College and is a Certified Public Accountant.- Jennifer Ziolkowski自2017年5月起担任我们的首席财务官兼财务主管。在加入我们之前,她曾于2014年至2017年担任梦百合公司Philips梦百合北美销售业务主管,并于2012年至2014年担任其北美高级财务总监。Ziolkowski女士从2010年到2012年担任医疗耗材和传感器总监,从2008年到2010年担任Imaging Systems的财务总监,从2007年到2008年担任TransMedics,Inc.的财务高级总监和公司财务总监,TransMedics,Inc.是一家医疗设备公司,并从2001年到2007年在Cytyc Corporation(一家医疗技术公司)担任多个金融和企业发展领导职位。从1996年到2001年,Ziolkowski女士在普华永道会计师事务所(PricewaterhouseCoopers LLP)获得了丰富的经验,在那里她担任高级交易服务顾问,并担任波士顿技术集团的审计高级和工作人员。Ziolkowski女士拥有波士顿学院(Boston College)会计学士学位,是一名注册会计师。
- Jennifer Ziolkowski has served as our Chief Financial Officer since March 2021. Prior to joining Vigil, Ms. Ziolkowski was Chief Financial Officer of Solid Biosciences Inc. NASDAQ: SLDB from May 2017 to January 2021 where she played a key role in transforming Solid from a private, preclinical company to a publicly-held, clinical-stage biotech company. Previously, Ms. Ziolkowski held various leadership positions at Philips Healthcare from August 2008 to May 2017 most recently as Head of Sales Operations, North America of Philips Healthcare from 2015 to May 2017. Prior to Phillips, Ms. Ziolkowski was Senior Director of Finance and Corporate Controller of TransMedics, Inc. from April 2007 to July 2008 where she played a critical role in building the company's financial operations. Ms. Ziolkowski established her career within the healthcare industry at Cytyc Corporation (acquired by Hologic, Inc. (NASDAQ:HOLX)) from May 2001 to April 2007. Ms. Ziolkowski began her career at PricewaterhouseCoopers LLP from September 1996 to April 2001. Ms. Ziolkowski holds a BS in Accounting from Boston College and is a Certified Public Accountant.
- Lynette Herscha
Lynette Herscha自2019年1月起担任我们的首席法务官兼秘书。在加入我们之前,她曾于2017年至2018年担任上市生物制药公司ConcertPharmaceuticals,Inc.的总法律顾问,秘书和执行团队成员,并于2014年至2017年担任其Vice President,法律和助理秘书。在加入Concert Pharmaceuticals之前,Herscha女士于2006年至2014年在MomentaPharmaceuticals,Inc.(一家上市生物技术公司)和Phase Forward,Inc.(一家上市技术公司)担任多个高级法律职位。她的职业生涯始于任职Fulbright&Jaworski公司的律师事务所。Herscha女士拥有波士顿大学法学院(Boston University School of Law)的法学博士学位和波士顿大学(Boston University)的文学学士学位。
Lynette Herscha has served as our Chief Legal Officer and Secretary since January 2019. Prior to joining us, she served as General Counsel, Secretary and a member of the Executive Team at Concert Pharmaceuticals, Inc., a public biopharmaceutical company, from 2017 to 2018 and its Vice President, Legal and Assistant Secretary from 2014 to 2017. Before joining Concert Pharmaceuticals, Ms. Herscha held various senior legal positions at Momenta Pharmaceuticals, Inc., a public biotechnology company, from 2006 to 2014 and Phase Forward, Inc., a public technology company, from 2000 to 2006. She began her career at the law offices of Fulbright & Jaworski. Ms. Herscha holds a J.D. from Boston University School of Law and a B.A. from Boston University.- Lynette Herscha自2019年1月起担任我们的首席法务官兼秘书。在加入我们之前,她曾于2017年至2018年担任上市生物制药公司ConcertPharmaceuticals,Inc.的总法律顾问,秘书和执行团队成员,并于2014年至2017年担任其Vice President,法律和助理秘书。在加入Concert Pharmaceuticals之前,Herscha女士于2006年至2014年在MomentaPharmaceuticals,Inc.(一家上市生物技术公司)和Phase Forward,Inc.(一家上市技术公司)担任多个高级法律职位。她的职业生涯始于任职Fulbright&Jaworski公司的律师事务所。Herscha女士拥有波士顿大学法学院(Boston University School of Law)的法学博士学位和波士顿大学(Boston University)的文学学士学位。
- Lynette Herscha has served as our Chief Legal Officer and Secretary since January 2019. Prior to joining us, she served as General Counsel, Secretary and a member of the Executive Team at Concert Pharmaceuticals, Inc., a public biopharmaceutical company, from 2017 to 2018 and its Vice President, Legal and Assistant Secretary from 2014 to 2017. Before joining Concert Pharmaceuticals, Ms. Herscha held various senior legal positions at Momenta Pharmaceuticals, Inc., a public biotechnology company, from 2006 to 2014 and Phase Forward, Inc., a public technology company, from 2000 to 2006. She began her career at the law offices of Fulbright & Jaworski. Ms. Herscha holds a J.D. from Boston University School of Law and a B.A. from Boston University.